INCYTE CORP (INCY)

Incyte is a global biopharmaceutical company that discovers, develops and commercializes proprietary therapeutics. Its global headquarters is in Wilmington, Delaware, where it conducts discovery, clinical development and commercial operations. It also runs clinical development and commercial operations from its European headquarters in Morges, Switzerland, other European offices, a Japanese headquarters in Tokyo and a Canadian headquarters in Montreal.

The company focuses on three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. The hematology franchise has four approved products: JAKAFI (ruxolitinib) for myelofibrosis, polycythemia vera and acute and chronic graft-versus-host disease; ICLUSIG (ponatinib) for chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia in Europe and select countries; MONJUVI/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, for which Incyte holds exclusive global rights; and NIKTIMVO (axatilimab-csfr) for chronic graft-versus-host disease, licensed from Syndax. Hematology pipeline programs include a once-daily ruxolitinib formulation, the mutant calreticulin antibody INCA033989, the bispecific INCA035784, and the JAK2V617F inhibitor INCB160058. The oncology franchise has two approved products, PEMAZYRE (pemigatinib) for cholangiocarcinoma and myeloid/lymphoid neoplasms with FGFR1 rearrangement, and ZYNYZ (retifanlimab-dlwr), a PD-1 antibody licensed from MacroGenics for Merkel cell carcinoma and anal canal squamous cell carcinoma. Its oncology candidates include the CDK2 inhibitor INCB123667 for ovarian cancer, the KRAS G12D inhibitor INCB161734 for pancreatic cancer, and the TGFβR2xPD-1 bispecific INCA33890 for colorectal cancer. The Inflammation and Autoimmunity franchise has one approved product, OPZELURA (ruxolitinib) cream, for atopic dermatitis and nonsegmental vitiligo. Its development programs include ruxolitinib cream in hidradenitis suppurativa, the oral JAK1 inhibitor povorcitinib in hidradenitis suppurativa, vitiligo, prurigo nodularis and asthma, and zilurgisertib for fibrodysplasia ossificans progressiva.

Incyte's products serve patients with rare blood cancers, graft-versus-host disease, lymphomas, solid tumors and immune-mediated dermatologic conditions. Approvals span the United States, the European Union, Japan, Canada, China and the U.K. Through partners, Incyte also earns milestones and royalties: Novartis sells ruxolitinib outside the United States as JAKAVI and also licenses TABRECTA (capmatinib), while Eli Lilly commercializes baricitinib (OLUMIANT) for rheumatoid arthritis, atopic dermatitis, alopecia areata and COVID-19.

In the United States, Incyte markets JAKAFI through its own specialty sales force and commercial team. It distributes the product mainly through specialty pharmacy providers and wholesalers that deliver by mail to patients or to the patient's pharmacy. The company holds composition-of-matter and use patents for ruxolitinib that expire in mid and late 2028, and ruxolitinib phosphate qualifies for the Small Biotech Exception under the Inflation Reduction Act. Incyte expanded its European presence in 2016 by acquiring ARIAD Pharmaceuticals' European operations. It also relies on collaborations and licenses, including with Merus's bispecific platform and Enable Injections' on-body delivery system.